Merck & Co.’s experimental cholesterol pill slashed levels of the artery-clogging plaque far more than older tablets in the ...

By Christy Santhosh March 30 (Reuters) - Drugmaker Merck said on Monday its oral drug met the main goal of meaningfully ...

March 30 (Reuters) - Merck's oral drug reduced bad cholesterol by up to 64.6% in a late-stage trial, the drugmaker said on ...

Merck & Co. has lifted the lid on the third successful phase 3 trial of its PCSK9 inhibitor, showing the edge the cardiovascular disease prospect has over other oral non-statin therapies.

Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non ...

The lack of a dose-response effect could be due to the high number of dropouts in the higher-dose Winrevair arm and the relatively small study population, a discussant for Merck explained.

Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...

Merck & Co. agreed to buy Terns Pharmaceuticals Inc. for $6.7 billion, giving the multinational company access to a promising ...

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

March 25 (Reuters) - Merck said on Wednesday it would buy biotech Terns Pharma in a deal valued at up to $6.7 billion, as the ...

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical ...

Merck has struck a $5.7bn deal to buy Terns Pharmaceuticals, a US biotech developing treatments for a rare form of blood and ...